ChemicalBook > CAS DataBase List > JNJ-7706621

JNJ-7706621

Product Name
JNJ-7706621
CAS No.
443797-96-4
Chemical Name
JNJ-7706621
Synonyms
CS-409;JNJ-7706621 ，S1249;JNJ-7706621 USP/EP/BP;JNJ7706621; JNJ 7706621;JNJ-7706621, 10 mM in DMSO;Aurora Kinase/Cdk Inhibitor;JNJ-7706621 JNJ7706621 Aurora Kinase Cdk Inhibitor;Aurora Kinase/Cdk Inhibitor - CAS 443797-96-4 - Calbiochem;4-[[5-Amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide;4-[[5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamide
CBNumber
CB62484646
Molecular Formula
C15H12F2N6O3S
Formula Weight
394.36
MOL File
443797-96-4.mol
More
Less

JNJ-7706621 Property

Melting point:
149-155℃
Boiling point:
676.6±65.0 °C(Predicted)
Density 
1.71
storage temp. 
+2C to +8C
solubility 
Soluble in DMSO at 15mg/ml
form 
White solid
pka
9.80±0.12(Predicted)
color 
White to off-white
Sensitive 
Light Sensitive
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H302Harmful if swallowed

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P304+P340IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

P405Store locked up.

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
189406
Product name
Aurora Kinase/Cdk Inhibitor - CAS 443797-96-4 - Calbiochem
Packaging
5mg
Price
$352
Updated
2025/07/31
Cayman Chemical
Product number
18494
Product name
JNJ-7706621
Purity
≥98%
Packaging
1mg
Price
$44
Updated
2024/03/01
Cayman Chemical
Product number
18494
Product name
JNJ-7706621
Purity
≥98%
Packaging
5mg
Price
$193
Updated
2024/03/01
Cayman Chemical
Product number
18494
Product name
JNJ-7706621
Purity
≥98%
Packaging
10mg
Price
$341
Updated
2024/03/01
TRC
Product number
J211310
Product name
JNJ-7706621
Packaging
50mg
Price
$865
Updated
2021/12/16
More
Less

JNJ-7706621 Chemical Properties,Usage,Production

Description

JNJ-7706621 is a dual inhibitor of cyclin-dependent kinases (CDKs) and Aurora kinases. It potently inhibits Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk3/cyclin E, Cdk4/cyclin D1, Cdk6/cyclin D1, Aurora A, and Aurora B in vitro (IC50s = 9, 4, 3, 58, 253, 175, 11, and 15 nM, respectively). It shows selectivity for these enzymes over a panel of other receptors and kinases, although it exhibits submicromolar inhibition of VEGF and FGF receptors, as well as GSK3β. JNJ-7706621 blocks the growth of a large variety of cancer cell lines (IC50 values range from 112 to 514 nM), with lower potency against normal cells (IC50 values between 3.67 and 5.42 μM). It induces the regression of A375 melanoma human tumor xenografts in mice. JNJ-7706621 is a substrate for the ATP-binding cassette transporter G2, also known as breast cancer resistance protein.

Uses

JNJ-770662 is a broad spectrum inhibitor of cyclin-dependent kinases and aurora kinases including CDK1/Cyclin B, CDK2/Cyclin A, CDK2/Cyclin E, Aurora-A and Aurora-B. JNJ-770662 has been shown to induce growth suppression and mitotic defects, these results suggest that JNJ-7706621 could be useful for cell cycle analysis and therapy of various cancers, including Ewing''s sarcoma.

Definition

ChEBI: 4-[[5-amino-1-[(2,6-difluorophenyl)-oxomethyl]-1,2,4-triazol-3-yl]amino]benzenesulfonamide is a sulfonamide.

Synthesis

172935-91-0

700805-72-7

443797-96-4

The general procedure for the synthesis of 4-[[5-amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamides from 2,6-difluorobenzohydrazide and N-[4-(aminosulfonyl)phenyl]-N'-cyanocarbamoyl phenyl ester (CAS: 700805-72-7) was as follows: a series of experiments were carried out to examine solvent and base effects on the yield of the target product as determined by HPLC. The experiments were performed as follows: N-[4-(aminosulfonyl)phenyl]-N'-cyanocarbamic acid phenyl ester (0.5 g, 1.60 mmol) and 2,6-difluorobenzoyl hydrazine (0.3 g, 1.74 mmol) were dissolved in 15 mL of the solvent of choice, and the base of choice was added with stirring (2.08 mmol, 1.3 eq., see Table 4). The reaction mixture was heated to 80-85 °C and maintained at this temperature for 6 hours. After completion of the reaction, the mixture was cooled to 20-25 °C and sampled for HPLC analysis.The HPLC samples were prepared by diluting aliquots with acetonitrile and water (50/50) to determine the percentage conversion to 4-[[5-amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulphonamide and the results are presented in Table 4. Table 4: Effect of solvent and base on the yield of the target producta,b. Different amounts of isourea exchange product and decomposition were observed in all cases, except for the case where pyridine was used.c. HPLC analysis showed c-3% of the other regional isomer.d. HPLC analysis showed ~1.4% of the other regional isomer.e. The results are presented in Table 4.

in vivo

JNJ-7706621 (100 and 125 mg/kg) is efficacious in a human tumor xenograft model under intermittent dosing regimens[3]. JNJ-7706621 (100 mg/kg, i.p.) exhibits 95% tumor growth inhibition in A375 (human melanoma) tumor xenograft model[1]. JNJ-7706621-loaded micelles inhibit tumor growth, and delay the tumor growth more efficiently than the control JNJ-7706621 suspension[4].

target

CDK1

IC 50

CDK6/cyclinD1: 175 nM (IC50); CDK2/cyclinE: 3 nM (IC50); Cdk4/cyclin D1: 253 nM (IC50); Cdk1/cyclin B: 9 nM (IC50); cdk2/cyclin A: 4 nM (IC50); CDK3/Cyclin E: 58 nM (IC50); Aurora A: 11 nM (IC50); Aurora B: 15 nM (IC50); VEGF-R2: 154 nM (IC50); VEGF-R1: 6400 nM (IC50); VEGF-R3: 735 nM (IC50); FGF-R1: 575 nM (IC50); FGF-R2: 226 nM (IC50); GSK3β: 254 nM (IC50)

References

[1] Patent: WO2005/77922, 2005, A2. Location in patent: Page/Page column 46
[2] Patent: WO2005/77922, 2005, A2. Location in patent: Page/Page column 48-49
[3] Patent: WO2005/77922, 2005, A2. Location in patent: Page/Page column 54-55
[4] Patent: WO2005/77922, 2005, A2. Location in patent: Page/Page column 50-51
[5] Patent: WO2005/77922, 2005, A2. Location in patent: Page/Page column 50-51

JNJ-7706621 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

JNJ-7706621 Suppliers

China 118 Germany 1 India 2 United Kingdom 1 United States 20 Global 142
VDM Biochemicals
Tel
0330-2528181
Fax
0330-2528171
Email
sales@vdmbio.com
Country
United States
ProdList
510
Advantage
64
AdooQ BioScience, LLC
Tel
+1 (866) 930-6790
Fax
+1 (866) 333-9607
Email
info@adooq.com
Country
United States
ProdList
2782
Advantage
58
ApexBio Technology LLC
Tel
+1-832-696-8203
Fax
+1-832-641-3177
Email
info@apexbt.com
Country
United States
ProdList
477
Advantage
60
Target molecule Corp.
Tel
857-239-0968
Fax
857-239-8801
Email
service1@targetmol.com
Country
United States
ProdList
2559
Advantage
60
Musechem
Tel
+1-800-259-7612
Fax
+1-800-259-7612
Email
info@musechem.com
Country
United States
ProdList
4660
Advantage
60
TargetMol Chemicals Inc.
Tel
+1-781-999-5354; +17819995354
Email
marketing@targetmol.com
Country
United States
ProdList
32435
Advantage
58
InvivoChem
Tel
+1-708-310-1919 +1-13798911105
Fax
708-557-7486
Email
sales@invivochem.cn
Country
United States
ProdList
6391
Advantage
58
Cckinase, Inc.
Tel
+1 (732)236-3202
Email
sales@cckinase.com
Country
United States
ProdList
2738
Advantage
58
Aladdin Scientific
Tel
Email
tp@aladdinsci.com
Country
United States
ProdList
57505
Advantage
58
TargetMol Chemicals Inc.
Tel
+1-781-999-5354;
Email
support@targetmol.com
Country
United States
ProdList
39035
Advantage
58
ApexBio Technology
Tel
--
Fax
--
Email
sales@apexbt.com
Country
United States
ProdList
6251
Advantage
58
American Custom Chemicals Corporation
Tel
--
Fax
--
Email
sales@acccorporation.com
Country
United States
ProdList
6820
Advantage
51
Santa Cruz Biotechnology, Inc.
Tel
--
Fax
--
Email
scbt@scbt.com
Country
United States
ProdList
3597
Advantage
60
Cayman Chemical Company
Tel
--
Fax
--
Email
cayman@caymanchem.com
Country
United States
ProdList
6213
Advantage
81
Creative Enzymes
Tel
--
Fax
--
Email
info@creative-enzymes.com
Country
United States
ProdList
6057
Advantage
58
Riedel-de Haen AG
Tel
--
Fax
--
Country
United States
ProdList
6773
Advantage
87
Matrix Scientific
Tel
--
Fax
--
Email
sales@matrixscientific.com
Country
United States
ProdList
6632
Advantage
80
Selleck Chemicals LLC
Tel
--
Fax
--
Email
info@selleckchem.com
Country
United States
ProdList
824
Advantage
60
Tinib-Tools
Tel
--
Fax
--
Country
United States
ProdList
164
Advantage
0
AK Scientific, Inc.
Tel
--
Fax
--
Email
sales@aksci.com
Country
United States
ProdList
6347
Advantage
65

443797-96-4, JNJ-7706621Related Search:

JNJ-10229570 JNJ0966 JNJ-38158471 N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine TRC253 3-(cyclopropylMethyl)-7-(4-phenylpiperidin-1-yl)-8-(trifluoroMethyl)-[1,2,4]triazolo[4,3-a]pyridine JNJ 63533054 JNJ-26481585 N-(4-chloropyridin-3-yl)-4-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)Methyl)piperazine-1-carboxaMide JNJ 31020028 JNJ-632 2-(4-Chlorophenoxy)-2-methyl-N-[5-[(methylsulfonyl)amino]tricyclo[3.3.1.13,7]dec-2-yl]-propanamide ZM 447439 Ribociclib Orantinib (SU6668) BI-D1870 CCT129202 AT9283

  • 4-[[5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamide JNJ7706621
  • 4-[[5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamide
  • Aurora Kinase/Cdk Inhibitor
  • Aurora Kinase/Cdk Inhibitor - CAS 443797-96-4 - Calbiochem
  • CS-409
  • JNJ7706621; JNJ 7706621
  • Benzenesulfonamide, 4-[[5-amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]-
  • 4-[[5-Amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide
  • JNJ-7706621 USP/EP/BP
  • JNJ-7706621 JNJ7706621 Aurora Kinase Cdk Inhibitor
  • Cyclin dependent kinase,CDK,JNJ-7706621,Apoptosis,JNJ7706621,inhibit,Inhibitor,Aurora Kinase
  • JNJ-7706621, 10 mM in DMSO
  • JNJ-7706621 ，S1249
  • 443797-96-4
  • C15H12F2N6O3S
  • Inhibitor
  • Inhibitors
  • JNJ-7706621